Tirzepatide
Tirzepatide (GIP/GLP-1 Dual Receptor Agonist)
The dual incretin
An FDA-approved dual agonist that activates BOTH the GIP and GLP-1 receptors (Mounjaro for type 2 diabetes, Zepbound for weight management). The added GIP arm makes it the most potent incretin for weight loss to date — SURMOUNT-1 showed up to ~22.5% body-weight reduction, and the head-to-head SURMOUNT-5 trial beat semaglutide directly. Like semaglutide, it is NOT metabolized by CYP enzymes — response variation is driven by receptor and pathway genetics, not liver metabolism.
Key Benefits
Most potent incretin weight loss to date — up to ~22.5% body weight (SURMOUNT-1)
Directly superior to semaglutide head-to-head (SURMOUNT-5)
Dual GIP + GLP-1 mechanism, not available with single agonists
Strong glycemic control in type 2 diabetes (SURPASS programme)
Once-weekly dosing via albumin/fatty-acid half-life extension
Mechanism of Action
How Tirzepatide works
Tirzepatide is a single molecule that engages two incretin receptors at once, which is why its effect size exceeds GLP-1-only agonists:
- GLP-1 receptor agonism — central appetite suppression (hypothalamus, brainstem), delayed gastric emptying, glucose-dependent insulin secretion and glucagon suppression — the same axis as semaglutide
- GIP receptor agonism — the differentiator. GIP enhances insulin sensitivity, improves adipose-tissue lipid handling, and appears to add a central appetite-regulating signal that complements GLP-1, reducing nausea relative to the weight loss achieved
- Synergistic weight loss — the dual mechanism produces greater appetite reduction and energy-balance shift than either pathway alone (SURMOUNT-1: ~15–22.5% across doses; SURMOUNT-5 superior to semaglutide)
- Glycemic control — SURPASS programme demonstrated HbA1c reductions exceeding GLP-1 monotherapy in type 2 diabetes
- Weekly dosing — fatty-acid acylation extends half-life to ~5 days, supporting once-weekly subcutaneous administration
Your Genetics & Tirzepatide
Genetic variants that affect your response
These SNPs determine how effectively Tirzepatide works for you specifically. A genetic peptide report identifies your variants before you start.
The Glu354Gln (E354Q) variant alters GIP receptor expression and signaling stability. Because tirzepatide's added potency over GLP-1-only agents comes from the GIP arm, GIPR genotype is uniquely relevant here (and not for semaglutide). Carriers have shown differential GIP-mediated metabolic and BMI responses in population studies — a marker that can favor tirzepatide over a GLP-1-only agonist.
The Ala316Thr variant affects GLP-1 receptor signaling efficiency and has been associated with differential weight-loss response. Tirzepatide still depends on the GLP-1 arm, so this variant modulates part of its effect alongside GIPR.
The strongest common type 2 diabetes risk variant. T-allele carriers have impaired beta-cell insulin secretion; tirzepatide's dual incretin insulin-secretory drive may partially compensate, but glycemic response magnitude varies by genotype.
Beta-arrestin 1 mediates incretin receptor internalization after activation. Variants influencing ARRB1 expression affect how quickly receptors are recycled, potentially shaping sustained response over months of treatment.
Which variants do you carry?
Upload your DNA data or order a kit to find out.
Evidence & Research
140+
Published studies
Multiple human clinical trials or CPIC-level pharmacogenomic data
Common Stacks
Tirzepatide is commonly combined with:
Frequently Asked Questions
Is tirzepatide better than semaglutide?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater weight loss than semaglutide. The likely reason is the added GIP receptor agonism on top of GLP-1. However, individual response varies — GIPR and GLP1R receptor genetics influence where you fall, which is exactly what a DNA report helps predict before you choose between them.
What genetics specifically favor tirzepatide?
Tirzepatide's edge over GLP-1-only drugs comes from the GIP arm, so GIPR variants (e.g. rs1800437) are uniquely informative here — they don't matter for semaglutide. GLP1R (rs6923761) and TCF7L2 (rs7903146) influence the shared GLP-1 and glycemic components.
Does tirzepatide interact with CYP enzyme genetics?
No. Like semaglutide, tirzepatide is a peptide cleared by general proteolysis, not cytochrome P450 metabolism. CYP2D6, CYP3A4 and other pharmacogenomic CYP variants do not affect its levels or dosing — response is governed by receptor and pathway genetics instead.
Learn More About Tirzepatide
genetics
Semaglutide vs Tirzepatide: Which Actually Works Better Based on Your GLP-1 Receptor Gene?
11 min read
peptide guides
Why Retatrutide Outperforms Ozempic and Mounjaro in Weight Loss (And Why It Isn't Approved Yet)
13 min read
genetics
Semaglutide and Your Genetics: Why Ozempic Works Differently for Everyone
16 min read
Your next move
Two ways forward with Tirzepatide.
Not sure it's for you?
Will Tirzepatide work for your genes — and at what dose?
Your report scores Tirzepatide against your receptor, CYP and pathway variants — likely responder, non-responder, and a sensible starting dose — in minutes.
Analyze my DNA — $99Already decided?
Get Tirzepatide from a vetted provider.
We rank licensed telehealth providers by price, safety and reviews — no brand pays for placement. Find the cheapest one that's actually legit.
Compare providers →